



Lipomics Moves to Larger Facility

Company to expand its lipomic profiling platform

WEST SACRAMENTO, California, Aug. 31, 2004 -- Lipomics Technologies, Inc., a privately held company that specializes in lipid metabolite analysis and interpretation, today announced that it has moved its operations to a new, larger facility at 3410 Industrial Boulevard in West Sacramento. Lipomics first began operations in June 2000 in West Sacramento's Technology Development Center, a business incubator for technology and life science companies established by the late Charlie Soderquist and his business partners.

The new facility, with almost five times more laboratory space, will allow Lipomics to expand its technical platform to study a broader array of lipid metabolites, including low-abundance lipids that are extremely difficult to detect and measure. Currently Lipomics measures approximately 400 distinct lipid metabolites.

Additionally, Lipomics plans to roll out new diagnostic tools based on recent discoveries of novel biomarkers for metabolic dysregulation. With lipids playing a central role in many of the industrialized world's leading disorders, Lipomics expects to be generating a steady flow of new diagnostic capabilities over the next several years. These tools will initially be used in clinical trial and research settings. Future applications in clinical practice promise more comprehensive and precise diagnostics of patient health compared to current diagnostic tools.

About Lipomics Technologies, Inc.

Lipomics develops tools for drug discovery and personalized medicine using proprietary technologies for lipid metabolism analysis and data interpretation. We generate a comprehensive understanding of lipid metabolism from plasma, serum or tissue samples by combining quantitative measurements of lipid metabolites with proprietary algorithms for mapping the lipomic profiles to biochemical pathways. In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technology to speed drug discovery processes, improve clinical trial stratification, reduce late-stage drug attrition, discover new biomarkers and develop early tests for monitoring drug response. More information about Lipomics can be found at www.lipomics.com

TrueMass®, Lipomics Surveyor®, and the Lipomics logo are registered U.S. trademarks and/or service marks of Lipomics Technologies, Inc. Lipomics Insight™ and Signature™ are trademarks used by Lipomics Technologies Inc in the U.S. and abroad.

#

EDITORIAL CONTACTS:

Sarina Chohan
(916) 371-7974
schohan@lipomics.com

Agency Contact

Doug Forsyth, Alchymia Communications
(541) 482-8744
df@alchymiacomm.com